Table 1.
The detailed information of the antibodies used in the present study.
Antibodies to | Clone | Dilution | Pretreatment | Source |
---|---|---|---|---|
Uroplakin II | BC21 | 1 : 100 | HIER | Biocare Medical, Concord, CA |
GATA3 | L50-823 | 1 : 100 | HIER | Biocare Medical, Concord, CA |
p40 | BC28 | 1 : 100 | HIER | Biocare Medical, Concord, CA |
p63 | 4A4 | 1 : 100 | HIER | Biocare Medical, Concord, CA |
CK7 | OV-TL 12/30 | 1 : 100 | HIER | Dako, Glostrup, Denmark |
CK20 | Ks20.8 | 1 : 100 | HIER | Dako, Glostrup, Denmark |
34βE12 | 34βE12 | 1 : 100 | HIER | Dako, Glostrup, Denmark |
GCDFP-15 | 23A3 | 1 : 200 | HIER | Dako, Glostrup, Denmark |
E-cadherin | NCH-38 | 1 : 100 | HIER | Dako, Glostrup, Denmark |
GCDFP-15: gross cystic disease fluid protein-15; HIER: heat-induced epitope retrieval.